Have to believe their on/off switch for CarT will be attractive for some biotech to purchase eventually. Not technologically best in class, but still appears to be a very effective way of controlling cytokine storms. The risk is others biotechs are also developing switches, some using vastly different approaches which could eventually become superior. The $8 level seems to be a good risk/reward level while waiting for a catalyst.
News 
Market Data 
Discover 
